These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 10785984)

  • 1. Choosing the most appropriate therapy for lipid disorders.
    Simons LA
    Aust Fam Physician; 2000 Mar; 29(3):199-203. PubMed ID: 10785984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW
    Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. When and how to treat hyperlipidemia.
    Kuo PT
    Prim Care; 1985 Mar; 12(1):77-89. PubMed ID: 3873080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid levels and cardiovascular risk in elderly women: a general population study of the effects of hormonal treatment and lipid-lowering agents.
    Dupuy AM; Carrière I; Scali J; Cristol JP; Ritchie K; Dartigues JF; Gambert P; Ancelin ML
    Climacteric; 2008 Feb; 11(1):74-83. PubMed ID: 18202967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of hypercholesterolaemia in the patient with diabetes.
    Packard C; Olsson AG
    Int J Clin Pract Suppl; 2002 Jul; (130):27-32. PubMed ID: 12296606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Achieving greater reductions in cardiovascular risk: lessons from statin therapy on risk measures and risk reduction.
    Ballantyne CM
    Am Heart J; 2004 Jul; 148(1 Suppl):S3-8. PubMed ID: 15211326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of hyperlipidaemia.
    Sum CF; Tan CE; Chew LS
    Singapore Med J; 1995 Aug; 36(4):410-6. PubMed ID: 8919159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of dyslipidemia in the high-risk patient.
    Stein EA
    Am Heart J; 2002 Dec; 144(6 Suppl):S43-50. PubMed ID: 12486415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The reality of treating dyslipidaemia in patients with coronary heart disease: a primary care survey.
    Wright DJ; Grayson AD; Jackson M; Dainty C
    Int J Clin Pract; 2003; 57(6):488-91. PubMed ID: 12918888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment gap in the use of lipid-lowering drug therapy in diabetes: a population-based study.
    James P; Tan HH; MacAlpine R; Brennan G; Emslie-Smith A; Morris AD
    Diabet Med; 2004 Oct; 21(10):1108-12. PubMed ID: 15384958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statins as the cornerstone of drug therapy for dyslipidemia: monotherapy and combination therapy options.
    Jones PH
    Am Heart J; 2004 Jul; 148(1 Suppl):S9-13. PubMed ID: 15211327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacologic treatment of type 2 diabetic dyslipidemia.
    Moon YS; Kashyap ML
    Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
    Sorensen SV; Frick KD; Wade A; Simko R; Burge R
    Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S
    Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
    Kłosiewicz-Latoszek L; Szostak WB; Grzybowska B; Białobrzeska-Paluszkiewicz J; Wiśniewska B; Stolarska I
    Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ezetimibe/simvastatin (INEGY) in the treatment of hyperlipidaemia.
    Kastelein JJ; Sankatsing RR
    Int J Clin Pract; 2005 Dec; 59(12):1464-71. PubMed ID: 16351680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid lowering treatment patterns and goal attainment in Nordic patients with hyperlipidemia.
    Svilaas A; Strandberg T; Eriksson M; Hildebrandt P; Westheim A
    Scand Cardiovasc J; 2008 Aug; 42(4):279-87. PubMed ID: 18609053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrates plus betaine: a winning combination?
    Lever M; George PM; Slow S; Elmslie JL; Shand BI; Scott RS; Chambers ST
    N Z Med J; 2010 Oct; 123(1324):74-8. PubMed ID: 20953225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacologic treatment of lipid metabolism disorders].
    Gmiński J
    Wiad Lek; 1996; 49(7-12):173-81. PubMed ID: 9214849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.